Iprotics Wins the Venture Challenge Spring 2022!
The winner of the Venture Challenge was announced today at the Dutch Biotech Event. The proud winner of the 2022 spring edition is Iprotics! The innovative startup Iprotics has developed specific proteasome inhibitors that potentially treat multiple myeloma (MM) without the side-effects known from traditional proteasome inhibitors.
According to the jury, composed of Carine van den Brink, Geert-Jan Mulder, Olga Liska, Daniela Begolo and Jan-Frens van Giessel, Iprotics is addressing a real need as experienced by patients suffering from multiple myeloma (MM). They have a clear value proposition on which they can expand in the future. Iprotics has developed a superior proteasome inhibitor compared to existing therapies. It is their aim to develop these leads to become the first-in-line treatment for MM patients. The unique compounds, for which IP protection is sought for and to which iProtics will obtain an exclusive license, inhibit with exquisite selectivity immunoproteasomes while leaving constitutive proteasomes intact. MM cells uniquely rely on immunoproteasomes for protein turnover and survival, whereas healthy tissue express constitutive proteasomes mostly. They have proof of concept in cell lines and primary patient tumour cells showing that their compounds efficiently and at low concentrations kill MM cells, but not healthy cells. Iprotics leads are expected to give less side effects and a considerably enlarged therapeutic window, and potentially increase patient lifespan and quality of life.
'We had a great idea but we did not know where to go with it. However, thanks to the Venture Challenge, we are now poised to start a company to develop our compounds and take them to the clinic'
- Elmer Maurits, founder of Iprotics
The Venture Challenge Spring started in April and today at the Dutch Biotech Event 2022 Iprotics takes home the €25.000 prize money to invest in their growth. The other highly-motivated participating teams were: Anatomy Projector, Autoscriber, INBORN and Novuxion.
Participating in the Venture Challenge leads to a clear venture plan, as well as to investor-ready pitches. The LifeSciences@Work Accelerator is powered by Health~Holland, Top Sector Life Sciences & Health. Contact Elmer Maurits for more information about Iprotics and read the LUMC press release.
Startup teams learn to identify key risks, analyse customer value propositions, develop a validation strategy, learn to build a venture plan and, ultimately, get connected to Life Sciences experts, investors and seasoned entrepreneurs. Read more. LifeSciences@Work: The national accelerator for high potential Life Sciences start-up initiatives. We help scientists build their business. We offer activities designed for researchers with entrepreneurial aspirations as well as for life sciences startups. LS@W is powered by Health~Holland | Top Sector Life Sciences & Health. Contact us.
Want to participate in the next venture challenge? Click here for more information.
©2022 Photo’s: Nils van Houts